The delisting risk is deferred but not resolved — monitor quarterly progress updates and any capital raises or reverse splits needed to meet NYSE American continued listing standards. The patent and manufacturing news is positive for the pipeline but does not change the near-term listing overhang.
Price Chart
Executive Summary
Actinium Pharmaceuticals received NYSE Regulation acceptance of its compliance plan, granting a maximum extension through November 27, 2027, to regain compliance with continued listing standards (Sections 1003(a)(ii) and (iii)). While this avoids immediate delisting risk, the company remains non-compliant and faces ongoing review. The press release also highlights patent and manufacturing advances for Actimab-A, but these are forward-looking and do not change the fundamental listing risk.
Key Facts
- NYSE Regulation accepted Actinium's compliance plan on August 12, 2026, granting a plan period through November 27, 2027.
- The company is not in compliance with Sections 1003(a)(ii) and (iii) of the NYSE American Company Guide.
- Failure to regain compliance or make progress consistent with the plan may lead to delisting proceedings.
- The company announced patent issuances and an additional manufacturer for Actimab-A, with clinical milestones expected from H2 2026 through 2027.
- Market cap is approximately $30M with a $30M market cap and 78% analyst bullishness.
Financial Impact
No financial figures reported in the filing. The delisting extension avoids immediate liquidity impact but ongoing non-compliance creates overhang.
Risk Factors
- Failure to regain compliance by November 27, 2027 could result in delisting, severely reducing liquidity and institutional ownership.
- The company may need to raise capital or execute a reverse stock split to meet listing standards, which could be dilutive.
- Clinical milestones are forward-looking and subject to regulatory and operational risks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-090232 |
| Document: ea030189001ex99-1.htm | 0001213900-26-090232 |
| Document: 0001213900-26-090232-index-headers.html | 0001213900-26-090232 |
| Document: 0001213900-26-090232-index.html | 0001213900-26-090232 |
| Document: 0001213900-26-090232.txt | 0001213900-26-090232 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | DEF 14A | $1.13 | awaiting T+20 | — | $1.40 (+23.72%) |
Oct 15, 2026 10d ago | 8-K | $1.13 | awaiting T+20 | — | $1.40 (+23.72%) |
Aug 14, 2026 10w ago | Press Release | $1.05 $1.25 | ▲ +19.05% | ▲ +21.03% | $1.40 (+33.14%) |
Aug 14, 2026 10w ago | 8-K | $1.05 $1.25 | ▼ −19.05% | ▼ −21.03% | $1.40 (−33.14%) |
Jun 18, 2026 18w ago | 8-K | $1.03 $0.9219 | ▲ +10.50% | ▲ +10.35% | $1.40 (−35.73%) |
May 29, 2026 21w ago | 8-K | $1.18 $0.9800 | ▲ +16.95% | ▲ +15.65% | $1.40 (−18.47%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers